Roberto Iacovelli, Medical oncologist at Gemelli Polyclinic Foundation IRCCS, shared a post on X:
“Prof Catto presented at EAU25 the surgical outcomes to neoadj. durvalumab in NIAGARA trial for NMIBC. No change for type, timiming and complications.”
More posts featuring Roberto Iacovelli.
